Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 2/20 | 0.59 |
| ▸ | ALB | P02768 | 2/20 | 0.58 |
| ▸ | SLC5A2 | P31639 | 2/20 | 0.55 |
| ▸ | ESR1 | P03372 | 1/20 | 0.55 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.51 |
| ▸ | OXTR | P30559 | 1/20 | 0.51 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.51 |
| ▸ | HTRA2 | O43464 | 4/20 | 0.51 |
| ▸ | HTRA1 | Q92743 | 4/20 | 0.51 |
| ▸ | CA9 | Q16790 | 3/20 | 0.51 |
| ▸ | CA12 | O43570 | 2/20 | 0.51 |
| ▸ | CA1 | P00915 | 2/20 | 0.51 |
| ▸ | CA2 | P00918 | 2/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4401348 | 1.00 | FOLH1 (0.59) | FOLH1ALBSLC5A2ESR1AVPR2 | |
| SCHEMBL4403238 | 0.95 | ALB (0.58) | FOLH1ALBSLC5A2ESR1HTRA2 | |
| SCHEMBL4401282 | 0.94 | FOLH1 (0.60) | FOLH1ALBSLC5A2ESR1CA9 | |
| SCHEMBL15501046 | 0.93 | FOLH1 (0.59) | FOLH1ALBSLC5A2ESR1AVPR2 | |
| SCHEMBL23291875 | 0.89 | FOLH1 (0.54) | FOLH1ALBESR1HTRA2HTRA1 | |
| SCHEMBL15501043 | 0.85 | ALB (0.50) | FOLH1ALBESR1HTRA2HTRA1 | |
| SCHEMBL16295184 | 0.84 | FOLH1 (0.68) | FOLH1ALBSLC5A2ESR1HTRA2 | |
| SCHEMBL16561810 | 0.84 | FOLH1 (0.62) | FOLH1ALBSLC5A2ESR1CA9 | |
| SCHEMBL8521611 | 0.84 | FOLH1 (0.49) | FOLH1ALBESR1HTRA2HTRA1 | |
| SCHEMBL3289756 | 0.84 | FOLH1 (0.62) | FOLH1ALBSLC5A2ESR1AVPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070087400-A1 | Covalent tethering of functional groups to proteins and substrates therefor | PROMEGA CORPORATION | 2007-04-19 | — | — | US | disclosed |
| US-20070087400-A1 | Covalent tethering of functional groups to proteins and substrates therefor | PROMEGA CORPORATION | 2007-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070087400-A1 | Covalent tethering of functional groups to proteins and substrates therefor | WASF2, NOTUM, YIPF5 | FOLH1 63/4885ALB 4212/4885SLC5A2 4708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.